Article
Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch
Rating:
0.0
Views:
82
Likes:
1
Library:
1
Microbiome pioneer Seres Therapeutics faced numerous setbacks throughout the years in numerous fields, most prominently for its lead program in C. difficile infections. But the biotech has plotted a comeback after a major flop six years ago, and is confident enough to start seeking cash ahead of a possible market
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value